Bergström M, Eriksson B, Oberg K, Sundin A, Ahlström H, Lindner K J, Bjurling P, Långström B
Uppsala University PET Center, Sweden.
J Nucl Med. 1996 Jan;37(1):32-7.
We used PET to characterize the uptake and decarboxylation of 11C-L-DOPA in vivo in two patients with endocrine pancreatic tumors: one glucagonoma and one gastrinoma.
With L-DOPA labeled with 11C in the beta position, in which the radioactive label follows the molecule through decarboxylation to dopamine, significant uptake was observed in the tumors. With L-DOPA labeled in the carboxyl group, in which the label is rapidly eliminated from the tissue as 11CO2 if decarboxylation takes place, an almost complete lack of uptake is noted.
This study shows that, using selective position labeling, an in vivo action of enzymatic activity can be observed with PET and that significant decarboxylation occurs in the tested endocrine pancreatic tumors. Also, marked retention of radioactivity occurs after treatment with somatostatin analogs. It is hypothesized that this is a reflection of a reduction of exocytosis which is induced by this treatment.
我们使用正电子发射断层扫描(PET)来表征11C-L-多巴在两名内分泌胰腺肿瘤患者体内的摄取和脱羧情况:一名为胰高血糖素瘤患者,一名为胃泌素瘤患者。
对于β位用11C标记的L-多巴,放射性标记物会随着分子脱羧转化为多巴胺,在肿瘤中观察到显著摄取。对于羧基用11C标记的L-多巴,如果发生脱羧,标记物会作为11CO2迅速从组织中消除,几乎完全没有摄取。
本研究表明,通过选择性位置标记,PET可观察到酶活性的体内作用,且在受试的内分泌胰腺肿瘤中发生显著脱羧。此外,用生长抑素类似物治疗后会出现明显的放射性滞留。据推测,这反映了该治疗诱导的胞吐作用减少。